Overview
The advancement of covalent Bruton's tyrosine kinase inhibitors (cBTKi) into the first-line setting may be an attractive treatment approach for patients with Mantle Cell Lymphoma (MCL), however, current prospective studies have not demonstrated a survival advantage. This study aimed to understand the real-world characteristics and survival outcomes of using cBTKi as a first-line treatment for patients with MCL.
Researchers found that patients treated with cBTKi combined with an anti-CD20 antibody had better survival outcomes than those treated with cBTKi alone. The combination therapy group showed longer progression-free survival and overall survival. The findings suggest that adding an anti-CD20 antibody to cBTKi in first-line treatment could improve patient outcomes, particularly for older adults, highlighting the need for better treatment strategies for MCL.
Why this matters
Using real-world data, this research provides evidence that may improve understanding of treatment options for patients with MCL. This research also provides clear opportunities for future research to improve treatment strategies for patients with MCL.